Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 3Completed 2Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Multiple Myeloma 49Leukemia, Lymphocytic, Chronic, B-Cell 19Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma 12Recurrence 10Lymphoma, Mantle-Cell 9Lymphoma, Follicular 7Leukemia, Myeloid, Acute 7Waldenstrom Macroglobulinemia 6Neoplasms, Plasma Cell 6Myelodysplastic Syndromes 6Lymphoma, B-Cell, Marginal Zone 6Leukemia 6Lymphoma, T-Cell, Peripheral 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Burkitt Lymphoma 4Sezary Syndrome 3Prostatic Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Ovarian Neoplasms 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, B-Cell 3Immunoblastic Lymphadenopathy 3Hodgkin Disease 3Carcinoma, Non-Small-Cell Lung 3

Interventions

Carboplatin 103Pemetrexed 96pembrolizumab 78Docetaxel 78Cisplatin 72Paclitaxel 70Erlotinib Hydrochloride 50Gemcitabine 48Radiotherapy 42Nivolumab 35Bevacizumab 35atezolizumab 24Radiosurgery 24durvalumab 20Cyclophosphamide 17130-nm albumin-bound paclitaxel 15Vinorelbine 14Taxes 14Radiation 14Etoposide 13Ipilimumab 12Albumin-Bound Paclitaxel 12avelumab 11Drug Therapy 10Cetuximab 10spartalizumab 9Sorafenib 9trametinib 8osimertinib 8capmatinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Non-Small-Cell Lung × Lenalidomide × Clear all
NCT02963610 2021-12-30

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

Fox Chase Cancer Center

Phase 1/2 Terminated
3 enrolled 5 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT02018523 2018-01-18

Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer

Baylor College of Medicine

Phase 1 Terminated
7 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00179699 2005-11-07

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

Celgene

Phase 1 Terminated
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡